Decreased regional cerebral blood flow during interferon therapy

Hepatology Research

Volumn 9, Issue 1, 1997, Pages 1-8

  Sasaki, Masaru ^a   Sata, Michio ^a   Ishibashi, Masatoshi ^a   Uchimura, Naohisa ^a   Tanikawa, Kyuich ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebral blood flow; Depressive state; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; IOFETAMINE I 123; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PSYCHOSIS; RASH; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031455363     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(97)00072-7     Document Type: Article

References (15)

1. Mathew RJ, Meyers JS, Francis DJ, Semchuk KM, Mortel K, Claghorn JL. Cerebral blood flow in depression. Am J Psychiatry 1980;137:1449-50.
2. Bolwing TG. Regional cerebral blood flow in affective disorder. Acta Psychiatry Scand Suppl 1993;371:48-53.
3. 133Xe inhalation method. Seisin Igaku 1990;32:751-757 (Abstract in English).
4. Kanaya T, Yonekawa M. Regional cerebral blood flow in depression. Jpn J Psychiatry Neurol 1990;44:571-6.
5. 133Xe inhalation single photon emission computerized tomography in manic-depressive illness. Jpn J Clin Med 1994;N52:1180-1184 (Abstract in English).
6. Sackeim HA, Prohovnik I, Moeller JR. Regional cerebral blood flow in mood disorders. Arch. Gen. Psychiatry 1990;47:60-70.
7. Priestman TJ. Initial evaluation of human lymphoblastoid interferon in patient with advanced malignant disease. Lancet 1980;11:113-8.
8. Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA. Central nervous system toxicity of interferon. Br J Cancer 1983;47:419-22.
9. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-6.
10. Futami H, Chuuman T, Naoi T, Sawada A, Shigehira M, Tubouti H. Ocular complications during systemic interferon therapy. Jpn J Clin Ophthalmol 1994;48:533-7.
11. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991;99:557-61.
12. Brouty-Boye D, Zetter BR, Inhibition of cell motility by interferon. Science 1980;208:516-8.
13. Herbert JM, Savi P, Laplace, M-CI, et al. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 1993;328:268-270.
14. Blalock JE, Smith EM. Human leukocyte interferon (Hu1FN-α) potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981;101:472-8.
15. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-α with naltrexon. Cancer Invest 1995;13:561-6.